Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Hidetomo Kitamura"'
Autor:
Hiroyasu Muramatsu, Taichi Kuramochi, Hitoshi Katada, Atsunori Ueyama, Yoshinao Ruike, Ken Ohmine, Meiri Shida-Kawazoe, Rie Miyano-Nishizawa, Yuichiro Shimizu, Momoko Okuda, Yuji Hori, Madoka Hayashi, Kenta Haraya, Nobuhiro Ban, Tatsuya Nonaka, Masaki Honda, Hidetomo Kitamura, Kunihiro Hattori, Takehisa Kitazawa, Tomoyuki Igawa, Yoshiki Kawabe, Junichi Nezu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Abstract Myostatin, a member of the transforming growth factor-β superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeuti
Externí odkaz:
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
Autor:
Tatsuya Tamura, Hiroshi Noda, Eri Joyashiki, Maiko Hoshino, Tomoyuki Watanabe, Masahiko Kinosaki, Yoshikazu Nishimura, Tohru Esaki, Kotaro Ogawa, Taiji Miyake, Shinichi Arai, Masaru Shimizu, Hidetomo Kitamura, Haruhiko Sato, Yoshiki Kawabe
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Hypoparathyroidism and osteoporosis can be treated with parathyroid hormone, but frequent injections are required. Here the authors develop a small-molecule agonist for the parathyroid hormone type I receptor that can be administered orally, and demo
Externí odkaz:
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
Autor:
Mariko Noguchi-Sasaki, Tetsuhiro Soeda, Atsunori Ueyama, Atsushi Muto, Michinori Hirata, Hidetomo Kitamura, Kaori Fujimoto-Ouchi, Yoshiki Kawabe, Keiji Nogami, Midori Shima, Takehisa Kitazawa
Publikováno v:
TH Open, Vol 02, Iss 01, Pp e96-e103 (2018)
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with antit
Externí odkaz:
https://doaj.org/article/1712bb2b44cb44868c9c8979ff11ecd5
Autor:
Hidetomo Kitamura, Kohtaro Hayashi, Tomomi Nakashima, Katsuaki Shirai, Satoshi Suzuki, Takuro Kariya, Masaru Okamura
Publikováno v:
Journal of Comparative Pathology. 189:45-51
Summary In humans, atypical endometrial hyperplasia (AEH) is considered as a precancerous lesion of endometrial adenocarcinoma (EA), from which it must be distinguished. Precancerous lesions have not been reported in cats with EA. We now document the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b08831d46536b59efe048ba05ab72b3
https://doi.org/10.1016/j.jcpa.2021.09.003
https://doi.org/10.1016/j.jcpa.2021.09.003
Autor:
Meiri Shida-Kawazoe, Yoshinao Ruike, Kenta Haraya, Nobuhiro Ban, Ken Ohmine, Tomoyuki Igawa, Atsunori Ueyama, Hiroyasu Muramatsu, Yuji Hori, Yuichiro Shimizu, Rie Miyano-Nishizawa, Takehisa Kitazawa, Masaki Honda, Madoka Hayashi, Jun-ichi Nezu, Hidetomo Kitamura, Yoshiki Kawabe, Kunihiro Hattori, Momoko Okuda, Taichi Kuramochi, Tatsuya Nonaka, Hitoshi Katada
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021)
Scientific Reports
Scientific Reports
Myostatin, a member of the transforming growth factor-b superfamily, is an attractive target for muscle disease therapy because of its role as a negative regulator of muscle growth and strength. Here, we describe a novel antibody therapeutic approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::951076f88a18bafedc95a3adae225315
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
https://doaj.org/article/f5532204ebd94faaa523b4801829ed1c
Autor:
Yoshiaki Watanabe, Haruhiko Sato, Hidetomo Kitamura, Tomoya Kotake, Yoshikazu Nishimura, Masaru Shimizu, Takashi Emura, Kotaro Ogawa, Toru Esaki, Toshito Nakagawa, Akemi Mizutani, Yoshiyuki Furuta, Shinichi Arai, Hiroshi Noda, Masateru Ohta, Tatsuya Tamura, Yoshiaki Isshiki
Publikováno v:
Journal of Medicinal Chemistry. 63:5089-5099
We have previously shown that the oral administration of the small molecule hPTHR1 agonist PCO371 and its lead compound, 1 (CH5447240) results in PTH-like calcemic and hypophostemic activity in thyroparathyroidectomized rats. However, 1 was converted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e990e3b015767e8e07afcf1625e08030
https://doi.org/10.1021/acs.jmedchem.9b01743
https://doi.org/10.1021/acs.jmedchem.9b01743
Autor:
Yuki Iwayanagi, Kunihiro Hattori, Etsuko Fujii, Yoshiaki Takashima, Keiko Kasutani, Sohei Oyama, Masahiko Nanami, Hideki Adachi, Yoshiki Kawabe, Hidetomo Kitamura, Hiroaki Matsushita, Keiko Esaki, Akihisa Sakamoto, Tsukasa Suzuki, Taichi Kuramochi, Shin Shimaoka, Akihisa Kaneko, Masaaki Goto, Yoshinobu Higuchi
Publikováno v:
Experimental Dermatology. 27:14-21
Scratching is an important factor exacerbating skin lesions through the so-called itch-scratch cycle in atopic dermatitis (AD). In mice, interleukin (IL)-31 and its receptor IL-31 receptor A (IL-31RA) are known to play a critical role in pruritus and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04f2a90eb76872e04193b80f0e55dbed
https://doi.org/10.1111/exd.13236
https://doi.org/10.1111/exd.13236
Autor:
Tohru Esaki, Eri Joyashiki, Kotaro Ogawa, Tomoyuki Watanabe, Taiji Miyake, Hidetomo Kitamura, Tatsuya Tamura, Shinichi Arai, Masaru Shimizu, Hoshino Maiko, Masahiko Kinosaki, Yoshikazu Nishimura, Yoshiki Kawabe, Haruhiko Sato, Hiroshi Noda
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-14 (2016)
Nature Communications
Nature Communications
Parathyroid hormone (PTH) is essential for calcium homeostasis and its action is mediated by the PTH type 1 receptor (PTHR1), a class B G-protein-coupled receptor. Hypoparathyroidism and osteoporosis can be treated with PTH injections; however, no or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96bf93859661c7e6d366e09a8ba8bea6
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
https://doaj.org/article/26ff462ed34f4f31ab3d012ea2e86ed2
Autor:
Tetsuhiro Soeda, Motohiko Sato, Takehisa Kitazawa, Kazuki Yamaguchi, Tomoyuki Igawa, Hirotake Shiraiwa, Teranishi Yuri, Norihito Shibahara, Hidetomo Kitamura, Mina Ichiki, Hiroko Konishi, Kei Nishimura, Eri Joyashiki, Hikaru Koga
Publikováno v:
Blood. 136:19-19
Background Emicizumab (HEMLIBRA®) is a factor (F) VIII function-mimetic therapeutic bispecific antibody (BsAb) to FIXa and FX able to prevent bleeding in persons with hemophilia A (PwHA) when injected subcutaneously once every 1, 2 or 4 weeks. To de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32ef2ef4fe28d9ce9718ebc9cb713bbe
https://doi.org/10.1182/blood-2020-138958
https://doi.org/10.1182/blood-2020-138958
Autor:
Atsushi Muto, Kaori Fujimoto-Ouchi, Atsunori Ueyama, Takehisa Kitazawa, Keiji Nogami, Mariko Noguchi-Sasaki, Yoshiki Kawabe, Midori Shima, Tetsuhiro Soeda, Hidetomo Kitamura, Michinori Hirata
Publikováno v:
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 02, Iss 01, Pp e96-e103 (2018)
TH Open, Vol 02, Iss 01, Pp e96-e103 (2018)
Emicizumab is a humanized bispecific antibody that binds simultaneously to factor (F) IXa and FX replacing the cofactor function of FVIIIa. Because emicizumab recognizes FIX/FIXa and FX/FXa, a question may arise whether emicizumab competes with antit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d2baa39f713c9dd0630f77997b9c38d
https://pubmed.ncbi.nlm.nih.gov/31249933
https://pubmed.ncbi.nlm.nih.gov/31249933